Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
HCC
Advertisement
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
Advertisements
Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No....
Elevar Receives FDA Complete Response Letter
FORT LEE, N.J., July 10, 2026 Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued...
Rznomics Announces FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma
SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Ribo and Boehringer Advance siRNA MASH Program
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
HelioLiver Blood Test Shows Strong HCC Detection
IRVINE, Calif., May 6, 2026 Helio Genomics announced publication of landmark clinical data demonstrating that its HelioLiver™ multi-analyte blood...
Advertisement
